investing succesffuly to reach your goals investing succesffuly to reach your goals
Sensex 61460.30 151.39 (0.25%)
Nifty Pharma  Companies
Read More

Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software. Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries and made deep inroads especially in providing low cost equivalents of expensive drugs.Pharma outsourcing into India and low cost Healthcare services are expected to be the key areas of growth in the near future. In addition, the inherent potential of biotechnology has also attracted many new companies and this is also a key growth area for Indian companies. NSE Indices has developed Nifty Pharma Index to capture the performance of the companies in this sector.

*Select only two options max
*Select only two options max
Screen stocks using 10 pre-filtered screens to pick best companies.
×
×
Selected Stock Screener :

In the table below you will find important data on Nifty Pharma Companies Share prices, 52-week High and Low, PE ratio, etc. You will also get MoneyWorks4me's rating on Quality, Valuation, Price Trend and Overall Rating to assist you in taking informed stock investing decisions. Register or Download App to use these with ease.

Nifty Pharma companies as on Jan-2022
Company Name (M.Cap) Is it a good
buy now?
CMP Price
Change
Market
Cap (Cr)
52W
High
52W
Low
ROE P/E P/BV EV/
EBITDA
Dr. Reddy's Laboratories Ltd(L)
1
Q V PT
4,684 0.22% 77,777 5,614 4,136 11.24 39.65 4.19 19.97
Cipla Ltd(L)
1
Q V PT
911.9 0.15% 73,460 1,005 738.2 13.77 28.39 3.78 16.82
Lupin Ltd(L)
1
Q V PT
941.4 -0.12% 42,810 1,268 854.0 9.72 0.00 3.58 16.36
Torrent Pharmaceuticals Ltd(L)
1
Q V PT
3,204 0.52% 53,932 3,304 2,311 22.86 42.43 8.64 23.54
Sun Pharmaceutical Industries Ltd(L)
1
Q V PT
857.2 0.47% 2,04,711 871.0 550.7 12.82 32.82 4.13 23.50
Aurobindo Pharma Ltd(L)
2
Q V PT
691.0 0.77% 40,178 1,064 620.5 20.59 19.83 2.47 10.59
Divi's Laboratories Ltd(L)
1
Q V PT
4,635 0.13% 1,22,892 5,425 3,155 23.97 57.53 12.38 42.05
Biocon Ltd(L)
2
Q V PT
357.9 0.24% 42,873 465.5 314.9 3.69 348.00 5.37 -
Alkem Laboratories Ltd(L)
1
Q V PT
3,596 0.55% 42,762 4,068 2,544 23.73 23.88 4.98 21.66
Cadila Healthcare Ltd(L)
1
Q V PT
439.5 0.33% 44,845 673.7 408.4 19.45 9.35 2.77 14.45

When to buy Bluechip stocks for highest returns?

Nifty Pharma Companies FAQs

Intro:

Pharmaceuticals sector is one of the key sectors where Indian companies have created a global brand for themselves besides software. Indian companies have taken advantage of the opportunities in the regulated generics market in the western countries and made deep inroads especially in providing low cost equivalents of expensive drugs. In addition, the inherent potential of biotechnology has also attracted many new companies and this is also a key growth area for Indian companies. NSE Indices has developed Nifty Pharma Index to capture the performance of the companies in this sector.

Statistics:

The Nifty Pharma has delivered a CAGR of ~10% over the last decade. Pharma outsourcing into India and low cost Healthcare services are expected to be the key areas of growth in the near future. India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies ~50% of the global demand for various vaccines, 40% of generic demand in the US and 25% of all medicines in the UK. Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025.

The Union Cabinet has given its nod for the amendment of existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions.

The drugs and pharmaceuticals sector attracted cumulative FDI inflow worth US$ 16.50 billion between April 2000 and March 2020 according to the data released by Department for Promotion of Industry and Internal Trade (DPIIT).

Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biologicals, Ayush and herbal products and surgical.

India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics is expected grow at an average growth rate of around 30 per cent a y-o-y to reach US$ 100 billion by 2025.

India's domestic pharmaceutical market turnover reached Rs 1.4 lakh crore (US$ 20.03 billion) in 2019, up 9.8% from Rs 129,015 crore (US$ 18.12 billion) in 2018.

Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise.

The steps taken by the government to reduce costs and bring down healthcare expenses drives the revenues of the pharma companies. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies. Low manufacturing cost is the key advantage of Indian players and this drives their growth and profitability.

Pharma sector includes active pharmaceutical ingredients (API) industry which is a part of chemical industry. The API which happens to be the raw material used by pharma companies is manufactured by companies with speciality in chemical segments. Hence they are crucial part of the pharma chain. The sector comprises of the multiple companies specialized in generic drugs and having low manufacturing as their key advantage. Also there are some large size companies which are specialized in over-the counter drugs/ medical accessories (like inhaler by Cipla). Some companies aim for the mass market while some aim for the niche drugs.

The large size companies such as Cipla, Lupin, Sun Pharma own notable brands, have a distribution across the country, capacity to heavily spend on R&D due to their balance sheet size. Pharma companies tend to trade at premium valuations due to their defensive nature of business. The other ancillary companies are packaging companies and other contract manufacturing companies.

1. Sun Pharma
Established in 1983 by Mr. Dilip Shanghvi, Sun Pharma (SUN) is the Indian MNC that manufactures and sells pharmaceutical formulations and APIs primarily in India and the United States. Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States.
The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anti-cancers, steroids, peptides and controlled substances.
The 2014 acquisition of Ranbaxy made Sun the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest speciality generic company globally.

Sun Pharma Growth Parameters


2. Cipla
Founded by Khwaja Abdul Hamied in 1935, Cipla Limited is an Indian MNC, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. Cipla is the key player in OTC medical accessories like inhaler pump.

Cipla Ltd Growth Parameters

3. Lupin
Incorporated in the year 1968 by Desh Bandhu Gupta, Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Lupin's research program covers the entire pharma product chain like generic research, Advanced Drug Delivery Systems, Intellectual Property Management, Novel Drug Discovery and Development and Biotechnology Research.

Lupin Ltd Growth Parameters

There is no specific index fund or ETF that can give you an exposure to all the Pharma companies. One idea is to buy stocks in the Nifty Pharma index in proportion to their weights in the index. Another idea is to gain exposure via investing in funds like DSP Healthcare, Mirae Asset Healthcare, etc.
You can use the MoneyWorks4me Nifty Pharma Index Screener for shortlisting the top performing companies. For example, using the MoneyWorks4me’s screener we first shortlist the fundamentally strong companies (Identified by the ‘Green’ colour code) and then look for companies that have shown a strong profit growth in the last five years. We arrive at the following list of companies:
Company Name Is it a Right Stock? CMP Mkt Cap (Cr) 5Y Profit Growth
Alkem Laboratories Ltd.(L) Very Good 2779 32,941 28.23
Cipla Ltd.(L) Very Good 782 62,822 13.8
Torrent Pharmaceuticals Ltd.(L) Very Good 2,825 47,812 10.98
MoneyWorks4me can help you identify the best performing Pharma sector stocks. The decision maker allows for simple and effective analysis.

Decision Maker

Sign up now to start a successful investing journey!